Clinical Trials Logo

Plasma Cell Disorders clinical trials

View clinical trials related to Plasma Cell Disorders.

Filter by:
  • None
  • Page 1

NCT ID: NCT06286215 Not yet recruiting - Clinical trials for Plasma Cell Disorders

Registry of Patients With Plasma Cell Disorders

Registry PCD
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: - The incidence of plasma cell disorders both before and after malignancy - Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) - Progression free survival (PFS) - overall survival - factors influencing overall survival, progression-free survival, and time to progression - Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. - genetic characteristics of plasma cell disorder - cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

NCT ID: NCT06252948 Recruiting - Clinical trials for Plasma Cell Disorders

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Microbiome
Start date: December 29, 2021
Phase:
Study type: Observational

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

NCT ID: NCT02566265 Completed - Multiple Myeloma Clinical Trials

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

SHIVERING 2
Start date: September 2015
Phase: Phase 2
Study type: Interventional

The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer therapy and may reduce disease progression at the end of the flu season

NCT ID: NCT01362985 Completed - Lymphoma Clinical Trials

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

Start date: July 2009
Phase: Phase 4
Study type: Observational

Genzyme will evaluate/monitor the off label transplant use of plerixafor using data in the European Group for Blood and Marrow Transplantation (EBMT) registry. Off-label use of plerixafor will be collected for data entered over a 5 year time span (i.e., data entered into the registry between the date of European Union (EU) marketing authorization [31 July 2009] and 31 July 2014). The EBMT is a non-profit, scientific society representing more than 600 transplant centers mainly in Europe. The EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy, which includes registering all the activity relating to stem cell transplants. Data are entered, managed, and maintained in a central database with internet access; each EBMT center is represented in this database. The collection by the EBMT registry of reasons for the off-label transplant use of plerixafor shall provide information of a substantial number of patients who are representative of the patient population receiving plerixafor off-label.